The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No. Just an acknowledgement of complaint.
Barclays said they understand my frustration but they have not mishandled the situation!! Yet how come after 2years 3 months are they in physical and legal challenges?...which I hasten to add they have given no explanation at all.
Highly likely a cover up in the hope of being able to trade on the Nasdaq capital market at some point. They just ignored this at the time. At the very least they should have informed their investors of the situation before delisting so an informed decision could have been made as to whether to sell.
I agree
2seabass
I sent them another email Friday for an update as what you say is exactly what they have said. So at least we know what there failings are, suggested another Post Office fiasco to them and that I will be seeking the assistance of the ombudsman if not solved.
Also stated that if the price moves to $6 ( we live in hope ) i will be sending them a sale request and if they are unable to trade then I will be looking to them for the value....
I guess they'll just suggest the ombudsman, have you had any luck with the ombudsman yet ?
Sturam007
I suggest you get in touch with Ombudsman.
Barclays informed me that they were going to create a trading platform for Nasdaq. It did eventually come live but a long time after they had hoped and way after the corporate action to de list and on to Nasdaq.
I strongly believe that they were hoping to trade our shares once it got up and running. However through lack of due diligence they failed because Tils is in fact on the capital market within the Nasdaq which is not incorporated in their platform. In my mind therefore the window of opportunity to provide a way of transferring our shares to another broker such as HL was lost. My complaints investigation got passed from pillar to post before they discovered this readily available information....now its physical and legal challenges they face to sort it out whilst we our denied any tenure whilst watching our investment going down the DRAIN!!
Compensation must be secured.
Transferred account from BSI to AJB prior to NASDAQ so do hold and can trade TLSA. However, if you are a long term holder of TLSA you will be entitled to Accustem shares which were spun out of TILS. When (if) ACUT eventually float on NASDAQ then you and I will face similar problems in trying to get Barclays to give us our shares.
Yes with Barclays too and same as you 2SEABASS, its a complete joke, and they just blame the other parties, very little we can do but wait. I'm in contact with them but haven't taken it to the ombudsman yet, lucky no reason to sell over the last couple of years !
You’ve got to be having a laugh? Over 2 years to get your entitlements?
I hold quite a few TILS & Accustem and can’t wait for a resolution whether it be months or years so I can sell and never revisit this again. I’ve been in for 3, 4 or 5 years now. Sick of it. To see the story change weekly just makes me laugh now. I suppose I’m relying on other gullible future investors to get me out of jail. Sad, but at least I’m honest
I've just notified the ombudsman that Barclay's still haven't sorted out the corporate action in Oct 2021 to list my shares on Nasdaq. Barclays have not upheld my complaint due to "physical and legal challenges "
Tiziana investor relations told me that many others made complaints regarding this unacceptable position with Barclays and went on to inform me that some have sought help from the ombudsman
IS THERE ANYONE ELSE OUT THERE IN THE SAME POSITION AS MYSELF?
Again watch the proactive video about accustem
It’s been what 6 months now since the last update?
Are they alive? Do they have any funding?
It’s been over 1000 days I think since the demerger.
Anything happening at all whatsoever?..
I like that bit at the end the company maybe aloud an additional 180 days plenty of time yet for it to come good. I for one think it will there isn't a pile of news coming out but what there is seems to be good
New York, July 21, 2023 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “Notice”) on July 19, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 Minimum Bid Price Requirement for continued listing of the Company’s common shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The
Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until January 16, 2024 (the “Compliance Deadline”), to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the Company’s ordinary share’s meet or exceed $1.00 per ordinary share for at least ten consecutive business days.
The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. Tiziana intends to monitor the closing bid price of its common shares and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance by the Compliance Deadline, the
Company may be afforded an additional 180 calendar day period to regain compliance.
The Company intends to resolve the deficiency and regain compliance with the Listing Rules.
GLA
BB
Tomorrow night D. DAY unless we get an extension 🤞
I am as interested in Accustem as I am in Tils :-)
Neither Tils or ACUT are listed on the London Stock Exchange so arguably neither are relevant on here but it's still a good place to talk about them. And tbh, the posts on neither are blocking up the board very much..
Given this is a Tiziana bulletin board, I would imagine that most people who visit this page are interested in its news.
As for Accustem, I suggest you email the board if you would like to find out further
Who cares, what’s happening with accustem?
New RNS update:
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients (10 total) are planned to be available in late January.
Tarun Singhal, M.B.B.S., M.D., Director of PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, and Associate Professor of Neurology at Harvard Medical School, commented, “Upon review of the baseline and three-month [F-18] PBR06 PET scans of the two new na-SPMS EA patients, a qualitative reduction in microglial activity was seen in one of two new patients. When combined with my assessment of the first six EA patients at three-months, a total of six out of the eight suggested a reduction in qualitative microglial PET signal. These findings are promising from an imaging standpoint and further studies are needed to confirm them using additional quantitative approaches.”
“The EA patient having a qualitative improvement in their PET scan also improved in their Modified Fatigue Impact Scale,” stated Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital. “Six out of the eight na-SPMS EA patients studied so far have seen measurable clinical improvement in their fatigue. I am excited to lead the effort to replicate these findings in the ongoing Phase 2 dose-ranging, randomized, placebo-controlled clinical trial.”
Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences noted “We’ve seen continued clinical and qualitative PET scan improvement over time in patients with na-SPMS where intranasal foralumab targets inflammation in the brain. It is my expectation that we will rapidly progress our ongoing Phase 2 trial of intranasal foralumab, given the encouraging results seen so far under the EA IND."
https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sciences-announces-updated-clinical-and-pet-scan
They should get the 180 day extension again.
TLSA share price must reach $1 by end of play Tuesday 16th January, or we are booted off NASDAQ. Very good news today, so what else a GC got up his sleeve to boost the share price?
We believe the risk reduction could be substantial with combination therapy.”
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.
Effectiveness of GLP-1ra non T2D obesity was recently shown in the >17,600 patient SELECT trial by Novo Nordisk (N Engl J Med 2023; 389:2221-2232(NCT03574597). SELECT showed a 20% reduction of major adverse cardiovascular events (MACE) such as heart attack, stroke, and peripheral vascular disease, with semaglutide. The risk of adverse cardiovascular events could be reduced further by the combination of intranasal foralumab and a GLP-1ra. The patent application describes the potential for foralumab to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease. Foralumab given with GLP-1ra may contribute importantly to further risk reduction in this at-risk patient population.
“The GLP-1ra’s have revolutionized the treatment of obesity and type 2 diabetes. Obesity and type 2 diabetes are associated with inflammation in the liver, adipose and vascular tissue. This inflammation contributes to the pathogenesis of stroke,” commented Howard L. Weiner M.D. from Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System and Professor of Neurology. “Although effective, GLP-1ra’s do not completely mitigate the disease process and are associated with various side effects. Intranasal foralumab, a fully human anti-CD3, has shown efficacy in attenuating inflammation in humans with multiple sclerosis and COVID. Because intranasal foralumab induces regulatory T cells in a physiologic fashion, foralumab has novel anti-inflammatory properties that make it applicable to multiple disease conditions. Furthermore, it has had minimal side effects in both human and animal studies. We have now discovered intranasal anti-CD3’s positive effect in models of diet-induced obesity related to mitigating its complications. Intranasal anti-CD3 therapy also dramatically decreases inflammation and metabolic changes. Thus, we believe it has the potential to be an ideal therapy to be given in combination with the class of GLP-1ra approved drugs.”
Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences said, “I believe that our commitment to improving patient outcomes by using anti-CD3, or foralumab, in risk mitigation for MACE could be another exciting indication for foralumab. We hope our efforts will give a new therapeutic option to patients afflicted with Type 2 Diabetes and non T2D obesity that are receiving GLP-1 receptor antagonists. We believe the risk reduction could be substantial with com
No updates for 5 or 6 months. Obviously no cash left, no results, no SPO, no anything?…
Is going pop or is there funding? What’s the plan? BOD do you fancy updating shareholders? I know it’s only been 3 years so far but would a 5 min interview hurt?…
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status Scale (EDSS), QoL assessments, and the Modified Fatigue Impact Scale (MFIS), which assess parameters that are essential to a patient’s everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images is an integral component of this study.
"The successful consenting, screening, completion of the baseline PET scan, and dosing of our first patient in the intranasal foralumab Phase 2a trial has occurred seamlessly,” said Tanuja Chitnis, M.D., the Principal Investigator at Brigham and Women’s Hospital, a founding member-hospital of Mass General Brigham Healthcare System, and Professor of Neurology at Harvard Medical School. “My anticipation is this randomized placebo-controlled trial is the first step in bringing this potential treatment to patients that have na-SPMS, a disease with no approved therapy. Our experience in the Expanded Access Program provides sustainable hope for relief of symptoms in these patients with an unmet medical need.”
Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences said, “I believe that our dosing of the first patient confirms Tiziana’s ability to execute on its commitments and potential to advance our fully human intranasal anti-CD3 mAb, foralumab, using novel imaging methods and clinically relevant endpoints. We hope our efforts will give a new therapeutic option to patients afflicted with this devastating disease. Currently, there are no FDA approved treatments for na-SPMS.”
Matthew W. Davis, MD, RPh, Chief Operating Officer and Chief Medical Officer of Tiziana, added, “I am very pleased the first patient has been dosed and our team is committed to remaining on track with our milestones. We are poised to accelerate enrollment and anticipate data readout in Q4 2024. I believe the study results will reveal important aspects for optimizing clinical management of na-SPMS - particularly the potential for a reduction in MFIS scores.”
https://www.tizianalifesciences.com/news-item?s=2023-12-19-tiziana-life-sciences-doses-first-patient-in-phase-2a-trial-of-intranasal-foralumab-in-multiple-sclerosis
I wonder if we will get an update on accustem any time soon. It’s what, 5 months? Since the last accustem update
Tiziana Life Sciences Ltd
TLSA Bid Price NCM 7/19/2023
So I guess there'll be some serious ramping soon.
Beening selfish here but hope it's January. Late January thank again rockz